This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes. Psoriasis (PsO) patients initiating secukinumab were identified and indexed to the first secukinumab use using the most recent data at study initiation (data period: March 1, 2018 to August 31, 2019) and with a subsequent data refresh (data period: March 1, 2017 - July 31, 2020).
Study Type
OBSERVATIONAL
Enrollment
17,743
Included all the patients treated with secukinumab
Novartis Investigative Site
East Hanover, New Jersey, United States
Treatment satisfaction level at Baseline
Patient reported satisfaction with treatment effectiveness was captured on a 5-point scale - "I believe this treatment is effective in clearing my skin of psoriasis." (1 = strongly agree, 2 = somewhat agree, 3 = Neither agree nor disagree, 4 = Somewhat disagree, 5 = Strongly disagree; n, %) in the EMR data system. For this analysis, the responses were classified into three groups: 1. Satisfied with treatment effectiveness (1 = strongly agree, 2 = somewhat agree) 2. Dissatisfied with treatment effectiveness ( 4 = Somewhat disagree, 5 = Strongly disagree) 3. Neither satisfied nor dissatisfied with treatment effectiveness (3 = Neither agree nor disagree)
Time frame: Baseline
Treatment satisfaction level at 6 months post-index
Patient reported satisfaction with treatment effectiveness was captured on a 5-point scale - "I believe this treatment is effective in clearing my skin of psoriasis." (1 = strongly agree, 2 = somewhat agree, 3 = Neither agree nor disagree, 4 = Somewhat disagree, 5 = Strongly disagree; n, %) in the EMR data system. For this analysis, the responses were classified into three groups: 1. Satisfied with treatment effectiveness (1 = strongly agree, 2 = somewhat agree) 2. Dissatisfied with treatment effectiveness ( 4 = Somewhat disagree, 5 = Strongly disagree) 3. Neither satisfied nor dissatisfied with treatment effectiveness (3 = Neither agree nor disagree)
Time frame: 6 months after initiating treatment with secukinumab (The date of the first order or administration was the index date; index period: March 1, 2018 - January 31, 2020)
Age
Age information was reported
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Gender
Gender information was reported
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Number of patients at various regions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patient regions: Northeast, Midwest, South, West, Unknown
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Number of patients with different race
Race: White, Hispanic, African American, Asian, other/unknown
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Weight
Weight of patients was reported
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Number of patients at Index year
Number of patients at each index year were reported
Time frame: Study Period: March 1, 2017 - July 31, 2020
Number of patients with plaque psoriasis subtype
Plaque psoriasis subtype was categorized as: generalized plaque psoriasis, localized plaque psoriasis, localized scalp psoriasis, inverse psoriasis, palmoplantar psoriasis, guttate psoriasis, nail psoriasis, psoriasis vulgaris, ostraceous psoriasis, or plaque psoriasis with unknown subtype during the 12 month pre-index period (including index date)
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Number of patients with Plaque location
Plaque location was categorized as recorded in EMR, including hand, arm, leg, trunk, scalp, head and neck, other/unknown
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Comorbidities of interest
Comorbidities of interest during the 12 months pre-index were reported
Time frame: Baseline (March 1, 2017 - March 1, 2018)
Physician global assessment (PGA)
PGA is scored on a 6-point scale from 0-5: 0 = clear, 1 = minimal, 2 = mild, 3 =moderate, 4 = marked, and 5 = severe
Time frame: Baseline and 6 months post index including index date (The date of the first order or administration was the index date; index period: March 1, 2018 - January 31, 2020)
Total body surface area (TBSA)
Total body surface area (BSA) was expressed as the percentage of body surface involved; BSA values of \<3%, 3-10%, and \>10% (reported as n, %) will be considered as mild, moderate, or severe, respectively.
Time frame: Baseline and 6 months post index including index date (The date of the first order or administration was the index date; index period: March 1, 2018 - January 31, 2020)
Psoriasis-related therapy
The following categories were included: 1. Biologics 2. Methotrexate 3. Corticosteroids (oral/injection) 4. Topical therapy 5. Phototherapy and Psoralen plus ultraviolet A photochemotherapy (PUVA) 6. NSAID/salicylates 7. Other systemic plaque psoriasis therapy (Acitretin) 8. Apremilast (PDE4 inhibitor)
Time frame: 6 months post index including index date (The date of the first order or administration was the index date; index period: March 1, 2018 - January 31, 2020)